Navigation Links
Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
Date:4/14/2008

NEW YORK, April 14 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation announced a $5.6-million award to drive a Phase 2 clinical trial to investigate the potential of inosine -- a naturally occurring chemical that gives rise to urate in the body -- to slow or stop the progression of Parkinson's disease.

The work is being funded under the Foundation's LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) 2007 initiative. LEAPS 2007 was funded with a lead gift from the Edmond J. Safra Foundation, one of the most steadfast supporters of The Michael J. Fox Foundation since its inception.

Urate is a natural metabolite and major antioxidant in humans. Previous studies found that healthy people with higher urate levels in the blood had a reduced risk of developing PD. More recent work, including a study published today in the journal Archives of Neurology authored by two of the principal investigators on this LEAPS award, have linked higher urate levels to a possible slower progression of the disease.

The goals of this LEAPS award are to determine the safety of using inosine to raise urate levels, and to assess optimal dosage for therapeutic effect. Ninety people recently diagnosed with Parkinson's disease will be enrolled in a randomized, double-blind clinical trial to determine whether and at what dose inosine can safely elevate levels of urate in cerebrospinal fluid. Three months after enrollment, cerebrospinal fluid will be tested for urate levels. If a tolerable dose of inosine adequately increases urate in the cerebrospinal fluid, subjects will continue on treatment for up to two years to assess long-term safety.

"This project is precisely the sort of work that The Michael J. Fox Foundation exists to identify and drive forward for patients' benefit," said Katie Hood, the Foundation's CEO. "The study is based on interesting epidemiological observations, but because inosine is a publicly available compound, no corpo
'/>"/>

SOURCE Michael J. Fox Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
2. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
3. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
4. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
5. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
6. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
7. Gates Foundation Seeks Proposals for Innovative Global Health Research
8. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
9. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
10. Childrens Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD
11. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ... and approved all parts required to build nine ... to manufacture the new PCT-based instrument system.  The ... for shipment by mid-October and that additional Barozyme ... rate of about one per week thereafter.  ...
(Date:9/19/2014)... and ORLANDO, Fla. , Sept. ... Inspire therapy continues to grow, with the publication of ... on-line in Otolaryngology – Head and Neck ... a worsening of both objective and subjective measures of ... attribute Inspire therapy for the reduction in obstructive sleep ...
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia Therapeutics, ... clinical data for its lead candidate ITCA 650 (continuous ... with high baseline HbA1c levels at the 50 th ... Study of Diabetes (EASD). Data from the open-label, phase ... of blood sugar in patients with poorly controlled type ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... Diagnostics, one of the leading providers of arrhythmia ... technology with cardiac care to provide leading edge ... eCardio with machine-to-machine (M2M) wireless data ... of cardiac patients. eCardio,s monitoring solution on cardiac ...
... and SEATTLE, Oct. 7 VentiRx Pharmaceuticals, Inc., ... novel Toll-Like Receptor 8 (TLR8) candidates for the ... today results from its randomized, placebo controlled clinical ... rhinitis. The results demonstrated that VTX-1463 significantly improved ...
Cached Medicine Technology:AT&T and eCardio Diagnostics Team Up to Advance Cardiac Care Through Innovative Mobile Technology 2AT&T and eCardio Diagnostics Team Up to Advance Cardiac Care Through Innovative Mobile Technology 3VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis 2
(Date:9/19/2014)... NJ (PRWEB) September 19, 2014 Visiting ... provider of home health care, hospice and palliative care ... to ring the Opening Bell yesterday at the New ... New Jersey philanthropist and social entrepreneur to care for ... Health Group has always worked to meet the urgent ...
(Date:9/19/2014)... (HealthDay News) -- U.S. military troops deployed to sunny ... according to a new study. Many returning ... In some cases, military personnel developed blisters on their ... or size of their moles since being deployed overseas. ... for skin cancer, the study authors noted. "The ...
(Date:9/19/2014)... 2014 (HealthDay News) -- Although there is mounting ... most middle-aged and older adults in the United ... according to new research. Less than one-quarter ... set by the Department of Health and Human ... essential for promoting health and fitness and staying ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 The ... important partnership with the National Fire Protection Association ... The collaboration, formalized today in a Memorandum of ... Members, factories, workers and other stakeholders with information, ... help protect the health and safety of workers ...
(Date:9/19/2014)... intact cells to treat and cure disease is ... is hindered by the inability of doctors and scientists ... these cells in patients without resorting to invasive procedures, ... 17 in the online journal Magnetic Resonance in ... Diego School of Medicine, University of Pittsburgh and elsewhere ...
Breaking Medicine News(10 mins):Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3Health News:A better way to track emerging cell therapies using MRIs 2
... cycles, known as circadian rhythms, are important for proper ... health. Disruptions of circadian rhythms and sleep-wake cycles have ... study by Douglas Institute researchers unravels a possible basis ... of clock genes in multiple areas of the human ...
... April, 2011: In the context of rising levels of cardiovascular ... of Cardiology (ESC) announces that for the first time- the ... Asia Pacific Congress of Cardiology (APCC). The 18th edition ... Malaysia, from 5 to 8 May 2011. The ESC deputation ...
... producing large quantities of a much-needed new imaging agent for ... other diseases, and the first evidence that the material is ... oxide nanoparticle, which is inexpensive, and stays in the body ... in the Journal of the American Chemical Society . ...
... a compound derived from tobacco, reduced plaques associated with dementia ... disease, a study led by researchers at Bay Pines VA ... The findings are reported online in the Journal ... "We found a compound that protects neurons, prevents the progression ...
... research shows that high maternal viral load and co-infection ... factors associated with vertical transmission of the hepatitis C ... (CC) is associated independently with the spontaneous clearance of ... in the mother or children did not increase risk ...
... -- Global Bridges, a healthcare alliance for tobacco dependence ... the InterAmerican Heart Foundation (IAHF) in Dallas, Texas, announced ... for health care providers in Latin America on how ... developed in collaboration with several regional and global expert ...
Cached Medicine News:Health News:Researchers observe disruptions of daily rhythms in Alzheimer's patients' brains 2Health News:The European Society of Cardiology organizes educational program in Asia 2Health News:Tobacco-derived compound prevents memory loss in Alzheimer's disease mice 2Health News:Severity of hepatitis C and HIV co-infection in mothers contribute to HCV transmission to child 2Health News:Health care alliance for tobacco dependence treatment launches training in Mexico 2Health News:Health care alliance for tobacco dependence treatment launches training in Mexico 3
Jaws with fine teeth. Serrated handle with polished finish. Jaws: Wide, 4.5 mm. With thumb catch lock....
Straight shafts with heavy Elschnig teeth. Flat serrated handle with slide style lock and polished finished....
Serrated handle with polished finish. Non-magnetic. Straight tips: Delicate 11 mm. Most popular size or model....
Delicate strong curved serrated tips. Serrated handle with dull finish....
Medicine Products: